UFP Technologies Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 27, 2024 (with events reported through July 1, 2024), details UFP Technologies, Inc.'s completion of the acquisition of AJR Enterprises, LLC and the execution of a new credit facility to support the transaction.
Key Financial Metrics and Transaction Details
- Acquisition Price: $110 million in cash for 100% of AJR Enterprises, LLC membership interests, subject to working capital adjustments.
- Valuation Multiple: Approximately 6.5x AJR's 2023 adjusted EBITDA.
- Target Financials: AJR reported approximately $75 million in sales for the trailing 12 months ended March 31, 2024, primarily from a single major customer.
- Escrow: $4 million of the purchase price is held in escrow for indemnification.
- Debt Facility: A new $275 million Amended and Restated Credit Agreement was established, consisting of a $125 million term loan and a $150 million revolving credit facility.
- Outstanding Borrowings (as of July 1, 2024): Approximately $150 million total ($115 million term loan used for the acquisition; $35 million revolving).
- Liquidity: $114 million available to draw under the revolving credit facility after letters of credit.
- Interest Rates: SOFR plus 1.25% to 2.25% or Prime plus 0.25% to 1.25%, dependent on performance.
- Maturity: Credit facilities mature on June 27, 2029.
Material Changes
The Company has significantly altered its capital structure and operational footprint. The primary material change is the acquisition of AJR, a medical device contract manufacturer specializing in single-use patient safe handling devices. To finance this, the Company replaced its prior credit agreement (originally dated 2001) with a larger, extended facility. The new agreement increases the total facility size, extends the maturity date to 2029, and modifies interest rate margins based on leverage ratios exceeding 3X.
Guidance, Risks, and Covenants
- Covenants: The new credit agreement includes a minimum fixed-charge coverage covenant and a maximum total funded debt to EBITDA covenant. It also restricts certain payments, indebtedness, and investments.
- Non-Compete: Sellers and restricted parties have agreed to a seven-year non-compete period.
- Risks: The filing notes that the credit facility is subject to acceleration and additional fees in the event of default. Forward-looking statements regarding the acquisition are subject to risks and uncertainties that could cause actual results to differ materially.
- Use of Proceeds: Funds are designated for general corporate purposes, specifically funding the AJR acquisition and other permitted acquisitions.
Investor Verification Checklist
- Verify the final purchase price after working capital adjustments and the release of the $4 million escrow.
- Confirm the specific leverage ratio and fixed-charge coverage ratios post-acquisition to ensure compliance with the new credit covenants.
- Review the concentration risk associated with AJR's single major customer representing the majority of its $75 million in sales.
- Monitor the integration progress of AJR's manufacturing capabilities in St. Charles, Illinois, and Santiago, Dominican Republic.
- Assess the impact of the increased debt load ($150 million outstanding) on future interest expense and cash flow.